LoginSignup
United Therapeutics logo

United Therapeutics Stock

StockStock
ISIN: US91307C1027
Ticker: UTHR
US91307C1027
UTHR

Price

Frequently asked questions

What is United Therapeutics's market capitalization?

The market capitalization of United Therapeutics is $17.88B. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.

What is United Therapeutics's Price-to-Earnings (P/E) ratio?

The Price-to-Earnings (P/E) ratio (TTM) for United Therapeutics is 17.60. This ratio helps investors assess whether a stock is overvalued or undervalued compared to its earnings.

What is the Earnings Per Share (EPS) for United Therapeutics?

United Therapeutics's Earnings Per Share (EPS) over the trailing twelve months (TTM) is $22.75. EPS indicates the company's profitability on a per-share basis.

What are the analyst ratings and target price for United Therapeutics's stock?

Currently, 15 analysts cover United Therapeutics's stock, with a consensus target price of $302.75. Analyst ratings provide insights into the stock's expected performance.

What is United Therapeutics's revenue over the trailing twelve months?

Over the trailing twelve months, United Therapeutics reported a revenue of $2.76B.

What is the EBITDA for United Therapeutics?

United Therapeutics's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is $1.41B. EBITDA measures the company's overall financial performance.

What is the free cash flow of United Therapeutics?

United Therapeutics has a free cash flow of $898.10M. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.

What is the 5-year beta of United Therapeutics's stock?

The 5-year beta for United Therapeutics is 0.57. A beta value indicates the stock's volatility relative to the market; a beta greater than 1 means higher volatility.

How many employees does United Therapeutics have, and what sector and industry does it belong to?

United Therapeutics employs approximately 1,168 people. It operates in the Health Care sector, specifically within the Biotechnology & Drugs industry.

What is the free float of United Therapeutics's shares?

The free float of United Therapeutics is 43.82M. Free float refers to the number of shares available for public trading, excluding restricted shares.

Financials

Market Cap

 $17.88B

5Y beta

 0.57

EPS (TTM)

 $22.75

Free Float

 43.82M

P/E ratio (TTM)

 17.60

Revenue (TTM)

 $2.76B

EBITDA (TTM)

 $1.41B

Free Cashflow (TTM)

 $898.10M

Pricing

1D span
$394.04$403.96
52W span
$208.62$417.82

Analyst Ratings

The price target is $302.75 and the stock is covered by 15 analysts.

Buy

12

Hold

2

Sell

1

Information

United Therapeutics Corporation is a pharmaceutical company. It markets and sells commercial therapies to treat pulmonary arterial hypertension (PAH): Tyvaso DPI (treprostinil) Inhalation Powder (Tyvaso DPI); Tyvaso (treprostinil) Inhalation Solution (nebulized Tyvaso), which includes the Tyvaso Inhalation System; Remodulin (treprostinil) Injection (Remodulin); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca). Tyvaso DPI and nebulized Tyvaso are also approved to treat pulmonary hypertension associated with interstitial lung disease (PH-ILD). It also markets and sells an oncology product, Unituxin (dinutuximab) Injection (Unituxin) for treatment of high-risk neuroblastoma, and the Remunity Pump for Remodulin (Remunity). Tyvaso DPI is a drug-device combination product that incorporates the dry powder formulation technology and Dreamboat inhalation device technology used in MannKind’s Afrezza (insulin human) Inhalation Powder.

1,168

Biotechnology & Drugs

Health Care

Identifier

ISIN

US91307C1027

Primary Ticker

UTHR

Knockouts

Join the conversation
Sign upLogin